Logo

Biogen Signs an Exclusive License Agreement with Ionis for IONIS-MAPTRx

Share this

Biogen Signs an Exclusive License Agreement with Ionis for IONIS-MAPTRx

Shots:

  • Ionis to get $45M as license fee- additional milestone up to $155M plus royalties on sales and will also be responsible for P-I trial assessing IONIS-MAPTRx in patients with mild AD. Biogen will take care of all subsequent studies plus further development- including regulatory filings- and commercialization
  • In 2012- Ionis and Biogen collaborated to develop and commercialize up to three novel antisense medicines to treat neurodegenerative diseases while SPINRAZA is the first product commercialized in this agreement targeted for spinal muscular atrophy (SMA) and is also developing BIIB067
  • IONIS-MAPTRx   is a platform targeted to reduce production of the protein tau in the central nervous system and is currently evaluated in P-I for mild AD patients

Click here to read full press release/ article

| Ref: GlobeNewswire | Image: Biogen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions